ASX ANNOUNCEMENT

27 March 2025

Release of Securities from Mandatory Escrow

Vitrafy Life Sciences Limited (ASX: VFY), (**Vitrafy** or **Company**) advises in accordance with ASX Listing Rule 3.10A, the following restricted securities will be released from mandatory escrow as follows:

ASX Code	Securities	Escrow Release Date
VFYAC	276,274 Fully Paid Ordinary Shares	8 April 2025

The Company will apply for the quotation of these securities within 5 business days after the end of the escrow period in accordance with ASX Listing Rule 2.8.5.

As outlined in Vitrafy's Pre-Quotation Disclosure Statement dated 22 November 2024, the above securities will continue to be subject to voluntary escrow arrangements with the voluntary escrow period to end in respect of:

- 25% of the securities, after release of the audited accounts for the Company for the financial year ended 30 June 2025; and
- 75% of the securities, after release of the audited accounts for the Company the financial year ended 30 June 2026.

ENDS

This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Investor and Media Relations
Simon Martin
Chief Financial Officer
investors@vitrafy.com

About Vitrafy

Vitrafy has developed a proprietary range of smart cryopreservation hardware and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. This integrated system ensures the preservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the storage process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets. Vitrafy is headquartered in Melbourne, Australia, has an ISO13485 accredited Manufacturing Facility and Laboratory in Ballarat, Victoria and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit vitrafy.com.